We thank veterinarians and cat owners for sharing their experiences and recommendations so that we continue to improve the performance of Polyprenyl Immunostimulant™.

Based on your feedback and data, we learned that the addition of antibiotics markedly increases the success of treatment, especially in chronic URI patients. Therefore, we added and the USDA approved the following recommendation on the label of Polyprenyl Immunostimulant™ to treat feline rhinotracheitis:“Appropriate concurrent antibiotic use may be needed in the presence of secondary bacterial infections.”

The label change is an important step toward a more robust performance of Polyprenyl Immunostimulant™, and we look forward to hearing about your experiences.